# Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

> **NCT02565173** · PHASE3 · COMPLETED · sponsor: **Inotek Pharmaceuticals Corporation** · enrollment: 303 (actual)

## Conditions studied

- Primary Open-Angle Glaucoma (POAG)
- Ocular Hypertension (OHT)

## Interventions

- **DRUG:** trabodenoson 4.5% BID
- **DRUG:** trabodenoson 6.0% QD
- **DRUG:** trabodenoson 3.0% QD
- **DRUG:** timolol 0.5% BID
- **DRUG:** placebo BID

## Key facts

- **NCT ID:** NCT02565173
- **Lead sponsor:** Inotek Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02565173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02565173, "Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02565173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*